We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Test Predicts Whether Breast Cancer Metastasizes to the Brain

By LabMedica International staff writers
Posted on 08 Nov 2015
Women can live for years with breast cancer that has begun to spread around the body, but the exception is when the cancer spreads to the brain, which usually indicates a woman is in her last few months of life. More...


The molecular chaperone αB-crystallin is expressed in estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 ‘triple-negative’ breast carcinomas and promotes brain and lung metastasis.

An international team of scientists led by those at University of British Columbia, (Vancouver, BC, Canada) analyzed 969 breast cancer tumors which ultimately spread, or metastasized, to new sites in the body, from a database of almost 4,000 breast cancers from the British Columbia Cancer Agency(BCCA) and 141 had spread first to the brain. The BCCA cohort includes 3,987 formalin-fixed paraffin-embedded specimens from female patients with newly diagnosed, invasive breast cancer referred to BCCA from 1986 to 1992 that were used to construct large tissue microarrays (TMA) linked to detailed clinicopathological data and long-term outcomes with a median follow-up of 12 years.

TMAs were constructed from tissue blocks and αB-crystallin protein expression was evaluated by immunohistochemistry (IHC) using a mouse monoclonal antibody (Enzo Life Sciences; Farmingdale, NY, USA). Tumors were considered positive for αB-crystallin if there was any staining above background levels. The αB-crystallin protein expression was scored by a pathologist who was blinded to clinical outcomes. Samples with less than 50 tumor cells present in the TMA core were excluded from the analysis and the TMAs were digitally scanned.

In the 855Met data set, αB-crystallin gene (CRYAB) expression was an independent predictor of brain as the first distant site of relapse. In the BCCA series, αB-crystallin protein expression was an independent prognostic marker of poor breast cancer-specific survival. Among patients with metastases, αB-crystallin was the strongest independent predictor of brain metastasis and the only independent predictor of brain as the first site of distant metastasis. Expression of αB-crystallin was also associated with worse survival.

Maggie Cheang, PhD, a Senior Staff Scientist and co-leader of the study said, “Spread of breast cancer to the brain is unfortunately very dangerous, and usually leads to death within months. It's important to find new ways to identify women who are most at risk of their cancer spreading to the brain, so that doctors can work out which women might need more intensive or new treatments to try to keep their cancer at bay for longer. Our study linked a positive score in this test with quicker spread to the brain, and importantly showed the factor we were measuring is providing information on patient outcome independently of other biomarkers already measured in the clinic.” The study was published on October 21, 2015, in the journal npj Breast Cancer.

Related Links:

University of British Columbia 
Enzo Life Sciences 



Gold Member
Troponin T QC
Troponin T Quality Control
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
New
Autoimmune Disease Diagnostic
Chorus ds-DNA-G
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: Brain biomarkers of Alzheimer\'s disease can be detected as early as middle age (Photo courtesy of University of Shutterstock)

Blood-Based Biomarkers Could Detect Alzheimer's as Early as Middle Age

As the global population ages, Alzheimer's disease and other dementing diseases are becoming more prevalent. The disease processes leading to Alzheimer's symptoms can begin years or even decades before... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.